Visiogen Inc., an Irvine eye device maker, said Monday that it’s raised $40 million in financing from new and existing investors.
Visiogen makes the Synchrony, a replacement lens for cataracts and people who have trouble seeing up close.
The Novartis Venture Fund, a unit of Switzerland’s Novartis AG, was the lead investor. Others include CMEA Ventures of San Francisco and Three Arch Partners of Menlo Park.
Visiogen said the funding would support the global rollout of Synchrony. The company plans to send results of an investigational device exemption study to the Food and Drug Administration later this year and anticipates approval for Synchrony in 2010.
Visiogen already sells Synchrony in Europe.
Visiogen has raised some $80.5 million since its inception in 2001, including a $24 million financing in early 2007 and a $16.5 million round in 2004.
Chief Executive and founder Reza Zadno moved Visiogen to OC in 2005.
